Lapix Doses First Patient in Phase 1b Dermatitis Trial
LAPIX Therapeutics has dosed the first patient in a randomized, placebo-controlled Phase Ib study of LPX-TI641 in adults with...
Jon Napitupulu
Promising Lupus Drug LBL-047 Enters Phase 1 Trial
No efficacy data yet. Leads Biolabs and Dianthus have dosed the first subject in a double-blind, randomized, placebo-controlled Phase...
Remarkable Corneal Nerve Outcomes in Phase 2 Pain Study
In a randomized, double-masked Phase 2 trial in neuropathic corneal pain (NCP), patients treated with 0.05% urcosimod showed exploratory,...
Orelabrutinib SLE Study Meets Phase IIb Goal, Enters Phase III
In a 187-patient Phase IIb study in systemic lupus erythematosus (SLE), orelabrutinib 75 mg once daily achieved a 57.1%...
IO Biotech Reveals 5-Year Clinical Trial Outcomes in Nature
IO Biotech’s peptide vaccine IO102-IO103 combined with nivolumab delivered a median progression-free survival of 25.5 months, a median duration...
Imviva Doses First Patient in CAR-T Cell Therapy Trial
A first U.S. patient treated with Imviva’s allogeneic anti‑CD7 CAR‑T, CTD402, in the TENACITY‑01 study achieved a complete remission...
Secura Bio Highlights Progress in Phase 3 Terzo Study Update
Secura Bio has randomized 35 of 124 planned patients and activated 43 of 45 sites across ten European countries...
Biosplice Doses First Patient in Ovarian Cancer Trial
Biosplice Therapeutics has initiated dosing in an investigator-initiated Phase 1 study testing cirtuvivint, a pan-CLK/DYRK inhibitor, in combination with...
Neonc Technologies Announces Updated Clinical Trial Results
In an expanded 25-patient Phase 1/2a plus compassionate-use cohort of recurrent WHO Grade III/IV IDH1-mutant astrocytoma, intranasal NEO100 produced...
Elraglusib Shows Promising Results in Phase II Cancer Study
Median overall survival reached 18.6 months across 32 patients with metastatic salivary gland cancers treated with elraglusib plus carboplatin...